Description

Simple

A medication used to treat mood disorders, such as depression.

Clinical

An antidepressant agent used for the treatment of major depressive disorder that targets the 5-HT transporter and 5-HT1A receptors.

Overview

Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,2]. Vilazodone may also be associated with less sexual dysfunction and weight gain[3]. Vilazodone was given FDA approval on January 21, 2011[5,Read more

Pharmacology

Indication

Vilazodone is approved for treatment of major depressive disorder[Label,1, Read more

Pharmacodynamic

Vilazodone increases serotonin levels in the brain by inhibiting the reuptake of serotonin while acting as a partial agonist on serotonin-1A receptors[Label, Read more

Mechanism of action

Vilazodone selectively inhibits serotonin reuptake in the central nervous system as well as acting as a partial agonist of 5HT-1A receptors[Label, Read more

Absorption

Vilazodone's bioavailability is 72% when taken with food[Label,1].

Protein binding

96-99%[Label,1, Read more

Volume of distribution

Vilazodone's volume of distribution is unknown but large[Label,1]

Clearance

Clearance of vilazodone is 19.9-25.1L/h in patients with mild to moderate renal impairment compared to 26.4-26.9L/h in healthy controls[ Read more

Half life

25 hours[Label,1]. Other studies show a half life of 24±5.2h with a single 40... Read more

Route of elimination

1% of the dose is recovered unchanged in the urine and 2% of the dose is recovered unchanged in the feces[Label, Read more

Toxicity

There is a lack of clinical studies of vilazodone in pregnancy[Label]. Animal studies have shown the effects on offspring to be reduced fetal weight, increased mortality, delayed maturation, and decreased fertility in adulthood at doses well above the maximum recommended human dose[Label]. Clinical... Read more

Adverse Effects

Contraindications

  • Route:
    • Oral
  • Dose Form:
    • Tablet
  • Recommended Actions:
    • Avoid
  • Regions: US
  • With Categories Coadmin:
      • Name: Monoamine Oxidase Inhibitors
      • Drugbank Id: DBCAT001004
      • Mesh Id: D008996
  • Route:
    • Oral
  • Dose Form:
    • Tablet
  • Recommended Actions:
    • Avoid
  • Regions: US
  • With Drugs Coadmin:
      • Name: Linezolid
      • Drugbank Id: DB00601
  • Route:
    • Oral
  • Dose Form:
    • Tablet
  • Recommended Actions:
    • Avoid
  • Regions: US
  • With Drugs Coadmin:
      • Name: Methylene blue
      • Drugbank Id: DB09241

Food Interactions

  • Avoid alcohol.
  • Avoid St. John's Wort.
  • Take with food.

Interactions

Type in a drug name to check for interaction with Vilazodone
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The metabolism of (R)-warfarin can be decreased when combined with Vilazodone.
(S)-Warfarin
The metabolism of (S)-Warfarin can be decreased when combined with Vilazodone.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
The metabolism of Vilazodone can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
1-benzylimidazole
The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Vilazodone.
2,5-Dimethoxy-4-ethylamphetamine
The risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Vilazodone.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Vilazodone is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Vilazodone.
4-hydroxycoumarin
The risk or severity of adverse effects can be increased when Vilazodone is combined with 4-hydroxycoumarin.
4-Methoxyamphetamine
The metabolism of Vilazodone can be decreased when combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Vilazodone.
7-Nitroindazole
The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Vilazodone.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The metabolism of Vilazodone can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Abatacept
The metabolism of Vilazodone can be increased when combined with Abatacept.
Abediterol
The risk or severity of hypertension can be increased when Vilazodone is combined with Abediterol.
Abiraterone
The metabolism of Vilazodone can be decreased when combined with Abiraterone.
Acebutolol
The metabolism of Acebutolol can be decreased when combined with Vilazodone.
Aceclofenac
The risk or severity of hypertension can be increased when Vilazodone is combined with Aceclofenac.
Acemetacin
The risk or severity of hypertension can be increased when Vilazodone is combined with Acemetacin.
Acenocoumarol
The metabolism of Vilazodone can be decreased when combined with Acenocoumarol.
Acepromazine
The risk or severity of adverse effects can be increased when Acepromazine is combined with Vilazodone.
5 References
  1. 1 . Cruz MP: Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.PubMed: 22346333
  2. 2 . Chavan BB, Kalariya PD, Tiwari S, Nimbalkar RD, Garg P, Srinivas R, Talluri MVNK: Identification and characterization of vilazodone metabolites in rats and microsomes by ultrahigh-performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom. 2017 Dec 15;31(23):1974-1984. doi: 10.1002/rcm.7982.PubMed: 28875544
  3. 3 . Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU: A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract. 2013 Aug;17(3):160-9. doi: 10.3109/13651501.2013.794245. Epub 2013 May 29.PubMed: 23578403
  4. 4 . Boinpally R, Alcorn H, Adams MH, Longstreth J, Edwards J: Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. Clin Drug Investig. 2013 Mar;33(3):199-206. doi: 10.1007/s40261-013-0061-5.PubMed: 23417352
  5. 5 . FDA Drug Approval Package: Vilazodone Link